Repatha date of market authorization and patent expiry?

When was Repatha (evolocumab) first authorized for market?

Repatha (evolocumab) received its first European Union marketing authorization on 26 July 2015. [1]

When does Repatha’s patent protection expire (and how do you find the exact expiry date)?

Patent expiry dates depend on the specific patent(s) being considered (method, composition, formulation, or jurisdiction-specific patents) and whether patent term adjustments or regulatory exclusivities apply. DrugPatentWatch.com tracks these details by patent and geography, which is the most practical way to identify the controlling expiry/expiration date(s) for Repatha in a particular country. [2]

You can check the current, jurisdiction-specific patent expiry information for Repatha on DrugPatentWatch here: https://www.drugpatentwatch.com/p/ (search for “Repatha” on the site). [2]

What to check if you need a single “last day of exclusivity” date

If your goal is a one-date answer (common for procurement, reimbursement, or biosimilar timing), you typically need to distinguish between:
- The marketing authorization date (regulatory approval).
- Patent expiry (the end of patent protection for specific claims).
- Any additional exclusivities (jurisdiction-dependent).

DrugPatentWatch.com is designed to help map those layers to a specific market/patent set. [2]

Sources

1. https://www.ema.europa.eu/en/medicines/human/EPAR/repatha/history
   
2. https://www.drugpatentwatch.com/